CHCWM – Cancer & Hematology Centers of West Michigan

eFT226-0002 (Effector Therapeutics)

eFT226-0002 (Effector Therapeutics)

Description:  A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Intravenous Zotatifin (eFT226) in Subjects with Selected Advanced Solid Tumor Malignancies

Mechanism of Action:  eFT226 is a potent and selective inhibitor of translation of select mRNAs

Target Population:  .  ER positive breast cancer with FGFR amplifications, and NSCLC with KRAS G12C mutations (in combination with Sotorasib)

Study Design:  In Dose Escalation Study drug is administered IV weekly.